

Refine Search

Search Results -

Terms	Documents
L6 and q10	3

Database:

US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

Search History

DATE: Monday, June 05, 2006 [Printable Copy](#) [Create Case](#)

Set Name Query

side by side

Hit Count Set Name

result set

DB=USPT,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR

<u>L7</u>	L6 and q10	3	<u>L7</u>
<u>L6</u>	(lung or pulmonary) adj3 (surfactant) and vagina\$	109	<u>L6</u>
<u>L5</u>	(lung or pulmonary) adj3 (surfactant) same vagina\$	14	<u>L5</u>
<u>L4</u>	L3 and (q or coQ)	2	<u>L4</u>
<u>L3</u>	(lung or pulmonary) adj3 (surfactant) same mucosa\$	16	<u>L3</u>
<u>L2</u>	(lung or pulmonary) adj3 surfactant	1258	<u>L2</u>
<u>L1</u>	(coq or Q) same (lung or pulmonary) adj3 surfactant	5	<u>L1</u>

END OF SEARCH HISTORY

Refine Search

Search Results -

Terms	Documents
L3 and (q or coQ)	2

Database:

US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

Search History

DATE: Monday, June 05, 2006 [Printable Copy](#) [Create Case](#)

Set Name Query
side by side

Hit Count Set Name
result set

DB=USPT,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR

<u>L4</u>	L3 and (q or coQ)	2	<u>L4</u>
<u>L3</u>	(lung or pulmonary) adj3 (surfactant) same mucosa\$	16	<u>L3</u>
<u>L2</u>	(lung or pulmonary) adj3 surfactant	1258	<u>L2</u>
<u>L1</u>	(coq or Q) same (lung or pulmonary) adj3 surfactant	5	<u>L1</u>

END OF SEARCH HISTORY

Hit List

[First Hit](#)[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 5 of 5 returned.

☐ 1. Document ID: US 6846649 B1

Using default format because multiple data bases are involved.

L1: Entry 1 of 5

File: USPT

Jan 25, 2005

US-PAT-NO: 6846649

DOCUMENT-IDENTIFIER: US 6846649 B1

TITLE: Recombinant human mannan-binding lectin

DATE-ISSUED: January 25, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Thiel; Steffen	DK-8240 Risskov			DK
Jensenius; Jens Christian	DK-5230 Odense			DK
Jensen; Thomas Vorup	DK-8000 Arhus			DK

US-CL-CURRENT: [435/69.1](#); [530/396](#), [530/412](#), [530/413](#), [536/23.5](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	Index	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-------	----------

☐ 2. Document ID: US 6471968 B1

L1: Entry 2 of 5

File: USPT

Oct 29, 2002

US-PAT-NO: 6471968

DOCUMENT-IDENTIFIER: US 6471968 B1

TITLE: Multifunctional nanodevice platform

DATE-ISSUED: October 29, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Baker, Jr.; James R.	Ann Arbor	MI		
Tomalia; Donald A.	Ann Arbor	MI		

US-CL-CURRENT: [424/280.1](#); [424/1.11](#), [424/130.1](#), [424/277.1](#), [424/94.1](#), [514/44](#), [536/23.1](#), [536/24.1](#), [536/24.5](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	Index	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-------	----------

☐ 3. Document ID: WO 9835660 A1

L1: Entry 3 of 5

File: EPAB

Aug 20, 1998

PUB-NO: WO009835660A1

DOCUMENT-IDENTIFIER: WO 9835660 A1

TITLE: TRANSDERMAL, ORAL AND INTRAVENOUS PREPARATIONS OF 2,3-DIMETHOXY-5-METHYL-6--DECAPRENYL-1,4-BENZOQUINONE

PUBN-DATE: August 20, 1998

INVENTOR-INFORMATION:

NAME

COUNTRY

ENZMANN, FRANZ

DE

LACHMANN, BURKHARD

NL

INT-CL (IPC): A61 K 31/12; A61 K 47/00

EUR-CL (EPC): A61K009/00; A61K031/12

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	EMC	Draw D.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	---------

☐ 4. Document ID: EP 348967 A2

L1: Entry 4 of 5

File: EPAB

Jan 3, 1990

PUB-NO: EP000348967A2

DOCUMENT-IDENTIFIER: EP 348967 A2

TITLE: Synthetic lung surfactant preparation comprising lipids and polypeptides.

PUBN-DATE: January 3, 1990

INVENTOR-INFORMATION:

NAME

COUNTRY

MCLEAN, LARRY R

KRSTENANSKY, JOHN L

US-CL-CURRENT: 530/324

INT-CL (IPC): A61 K 37/02; C07 K 7/00

EUR-CL (EPC): C07K014/785

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	EMC	Draw D.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	---------

☐ 5. Document ID: US 20040228910 A1, WO 9835660 A1, EP 1007021 A1, CA 2280316 A1, EP 1007021 B1, DE 59800863 G, ES 2159938 T3, US 20020155151 A1

L1: Entry 5 of 5

File: DWPI

Nov 18, 2004

DERWENT-ACC-NO: 1998-456851

DERWENT-WEEK: 200477

COPYRIGHT 2006 DERWENT INFORMATION LTD

TITLE: Transdermal, oral or intravenous coenzyme=Q-10 preparation - also containing pulmonary surfactant to improve effect, used e.g. for treating diabetes, incontinence, psoriasis or neuro-dermatitis

INVENTOR: ENZMANN, F; LACHMANN, B

PRIORITY-DATA: 1997DE-1005231 (February 12, 1997), 1999CA-2280316 (August 13, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 20040228910 A1</u>	November 18, 2004		000	A61K009/127
<u>WO 9835660 A1</u>	August 20, 1998	G	012	A61K031/12
<u>EP 1007021 A1</u>	June 14, 2000	G	000	A61K031/12
<u>CA 2280316 A1</u>	February 13, 2001	E	000	A61K031/125
<u>EP 1007021 B1</u>	June 13, 2001	G	000	A61K031/12
<u>DE 59800863 G</u>	July 19, 2001		000	A61K031/12
<u>ES 2159938 T3</u>	October 16, 2001		000	A61K031/12
<u>US 20020155151 A1</u>	October 24, 2002		000	A61K009/127

INT-CL (IPC): A61 F 13/00; A61 K 9/127; A61 K 9/14; A61 K 9/70; A61 K 31/12;
A61 K 31/125; A61 K 47/00

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	RWC	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Terms

(coq or Q) same (lung or pulmonary) adj3
surfactant

Documents

5

Display Format: [Previous Page](#)[Next Page](#)[Go to Doc#](#)

[First Hit](#) [Fwd Refs](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L3: Entry 7 of 16

File: USPT

Aug 5, 1997

DOCUMENT-IDENTIFIER: US 5653996 A

TITLE: Method for preparing liposomes

Detailed Description Text (71):

Aerosolized liposomes, or liposome sprays are a convenient vehicle for applying the liposomes to nasal or oral mucosa, or for delivery into the respiratory tract. In one embodiment, the liposomes are formulated as a dilute aqueous suspension and sprayed from a conventional pump or squeeze spray bottle. Alternatively, the liposomes are formulated for use with fluorocarbon propellant solvents in a pressurized canister system. Liposomes are also desirably used with nebulizing equipment. Aerosol delivery of liposomes is particularly suited for delivery of lipids and passenger molecules to the lungs, for treating a lung condition or disease. For example, lung surfactant lipids and lung surfactant-associated proteins are desirably delivered via aerosolized liposome to an infant or other individual having or at risk of having respiratory distress. The liposomes may be aerosolized under conditions which produce aerosol particle sizes favoring particle deposition in a selected region of the respiratory tract, see e.g. Radhakrishnan, U.S. Pat. No. 5,192,528.

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

[First Hit](#) [Fwd Refs](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L3: Entry 9 of 16

File: USPT

Nov 9, 1993

DOCUMENT-IDENTIFIER: US 5260284 A

**** See image for Certificate of Correction ****

TITLE: Methods employing unique mixtures of polar and neutral lipids and sterol for lung surfactant replacement therapy

Detailed Description Text (3):

Recent studies by the present Applicant have indicated that many of the phospholipids found in a pulmonary fluid are also found along the length of the gastrointestinal tract, from the esophagus to the colon. These phospholipids appear to be concentrated on the mucosal surface which separates the digestive and absorptive epithelium from the luminal contents. The functional importance of phospholipids has been studied in greatest detail in the lung. It is now well recognized that pulmonary surfactants, which are high in phospholipids, play a vital role in minimizing the surface forces at the level of the alveoli, allowing the alveoli to remain open throughout the respiratory cycle.

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

[First Hit](#) [Fwd Refs](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L3: Entry 11 of 16

File: USPT

Aug 27, 1991

DOCUMENT-IDENTIFIER: US 5043329 A

**** See image for Certificate of Correction ****

TITLE: Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract

Detailed Description Text (3):

Recent studies by the present Applicant have indicated that many of the phospholipids found in a pulmonary fluid are also found along the length of the gastrointestinal tract, from the esophagus to the colon. These phospholipids appear to be concentrated on the mucosal surface which separates the digestive and absorptive epithelium from the luminal contents. The functional importance of phospholipids has been studied in greatest detail in the lung. It is now well recognized that pulmonary surfactants, which are high in phospholipids, play a vital role in minimizing the surface forces at the level of the alveoli, allowing the alveoli to remain open throughout the respiratory cycle.

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

[First Hit](#) [Fwd Refs](#) [Previous Doc](#) [Next Doc](#) [Go to Doc#](#)



Generate Collection

Print

L6: Entry 94 of 109

File: USPT

Apr 26, 1994

US-PAT-NO: 5306483

DOCUMENT-IDENTIFIER: US 5306483 A

TITLE: Phospholipid delivery system

DATE-ISSUED: April 26, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mautone; Alan J.	Morris Township, Morris County	NJ		

US-CL-CURRENT: 424/45; 424/450

CLAIMS:

We claim:

1. A process for preparing lipid crystals in combination with a therapeutically active agent comprising:

(a) preparing a mixture of one or more lipids and one or more spreading agents selected from the group consisting of cholesteryl esters, phospholipids, carbohydrates, and proteins, in powder form; the therapeutically active agent; and one or more fluorocarbon propellants, said lipids, said spreading agents, and said therapeutically active agent being insoluble in the propellants wherein the lipids are present in an amount of about 80 to 99.5 percent by weight and the spreading agents are present in an amount of about 0.5 to about 20 percent by weight, both based on the weight of the mixture; and

(b) evaporating the propellants from said mixture.

2. The process defined in claim 1 wherein, simultaneously with or after step (b), the product of the process is delivered to the point of use.

3. The process defined in claim 1 wherein the lipids are phospholipids, neutral lipids, or mixtures thereof.

4. The process defined in claim 3 wherein the phospholipids are any of the class known as phosphatidylcholine.

5. The process defined in claim 4 wherein the phosphatidylcholine is any fully saturated diacyl phosphatidylcholine.

6. The process defined in claim 1 wherein the phospholipid is a diacylphosphatidylglycerol.

7. The process defined in claim 1 wherein the phospholipid is a

diacylphosphatidylethanolamine.

8. The process defined in claim 1 wherein the phospholipid is a diacylphosphatidylserine.

9. The process defined in claim 1 wherein the phospholipid is a diacylphosphatidylinositol.

10. The process defined in claim 1 wherein the phospholipid is a sphingomyelin.

11. The process defined in claim 1 wherein the phospholipid is Cardiolipin.

12. The process defined in claim 1 wherein the phospholipid is a lysophospholipid.

13. The process defined in claim 1 wherein the phospholipid is a plasmalogen.

14. The process defined in claim 1 wherein the phospholipid is a diether phosphonolipid.

15. The process defined in claim 1 wherein the phospholipid is a dialkylphospholipid.

16. The process defined in claim 1 wherein the carbohydrates are glucose, fructose, galactose, pneumogalactan, or dextrose.

17. The process defined in claim 1 wherein the protein is selected from albumin and pulmonary surfactant specific proteins A or B or C or D or mixtures thereof.

18. The process defined in claim 1 wherein the cholesteryl ester is cholesteryl palmitate, cholesteryl oleate or cholesteryl stearate.

19. The process defined in claim 1 wherein the fluorocarbon propellants are chlorofluorocarbons, hydrofluorocarbons or mixtures thereof.

20. The product of the process defined in claim 1 wherein about 95% of said product particles are equal to or less than 16 microns in diameter.

[Previous Doc](#)

[Next Doc](#)

[Go to Doc#](#)